Cargando…
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
BACKGROUND: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-β peptide (Aβ(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephaliti...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers Ltd.
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825665/ https://www.ncbi.nlm.nih.gov/pubmed/19355849 http://dx.doi.org/10.2174/156720509787602852 |